To the Editor Alzheimer disease (AD) can be clinically devastating and costly, given its potential to profoundly impair quality of life and activities of daily living. Ross et al1 sought to evaluate cost-effectiveness of controversial novel antiamyloid monoclonal antibodies aducanumab and donanemab, which aim to slow AD progression. The US Food and Drug Administration (FDA), despite dissent of its expert advisory committee, approved aducanumab under the accelerated approval pathway in 2021, based on the surrogate end point of reduction in cerebral amyloid-β plaque, and is currently considering donanemab for accelerated approval on similar grounds.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cliff ERS, Kelkar AH. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value. JAMA Neurol. 2022;79(11):1204. doi:10.1001/jamaneurol.2022.3101
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.